Latest News
Cytokinetics Announces New Details on Upcoming Phase 2 Trial
Cytokinetics, in collaboration with Astellas, has announced further details about a planned Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). CK-2127107 is a skeletal muscle […]
Read More ›Cure SMA Publishes Journal Article on the Patient Voice
Cure SMA, along with collaborators from Biogen and the SMA Foundation, have published a paper in the journal BMC Neurology. Over the past year, we’ve completed 16 focus group sessions […]
Read More ›Jadon’s Hope Foundation Donates 10 New Tomato Feeder Seats
Cure SMA recently received a donation of 10 special tomato feeder seats from Jadon’s Hope Foundation. These were immediately sent out to families who were on a waiting list for […]
Read More ›Cure SMA-Funded Researchers Publish Paper in Journal Pediatrics
Cure SMA-funded researchers Rebecca Hurst Davis and Kathy Swoboda have published a paper, “Responses to Fasting and Glucose Loading in a Cohort of Well Children with Spinal Muscular Atrophy Type […]
Read More ›Isis Pharmaceuticals Announces SHINE, an Open-Label Extension Study
Isis Pharmaceuticals, Inc. announced that it has initiated an open-label extension study, SHINE. The SHINE study provides ISIS-SMNRx to infants and children with spinal muscular atrophy (SMA) who have completed […]
Read More ›Cure SMA to Host Clinical and Regulatory Webinar
On Monday, November 9, Cure SMA will be hosting a one-hour webinar on clinical trials and regulatory topics. The webinar will be held at 11:00am CST (9:00am PST/10:00am MST/12:00pm EST). […]
Read More ›